Antibodies News and Research

RSS

COVID immunity related to how bad you get it

Researchers at Stanford University in California have shown that severely ill patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection develop significantly higher levels of antibodies against the virus than asymptomatic individuals and outpatients.

18 Aug 2020

Cryo-EM experiments offer important clues to chicken pox infection

Despite decades of study, exactly how herpesviruses invade our cells remains something of a mystery. Now researchers studying one herpesvirus, the varicella zoster virus (VZV) that causes chicken pox, may have found an important clue: A key protein the virus uses to initiate infection does not operate as previously thought, researchers at Stanford University and the Department of Energy's SLAC National Accelerator Laboratory report August 18 in Nature Communications.

18 Aug 2020

Study to explore risks and benefits of breastfeeding during COVID-19

To breastfeed or not to breastfeed? Science has long supported that "breast is best," but COVID-19 has brought with it new questions related to the benefits and/or potential risks of breastfeeding during this pandemic.

18 Aug 2020

Absolute Antibody offers SARS-CoV-2 neutralizing antibodies derived from COVID-19 patients

Absolute Antibody Ltd. today announced the availability of SARS-CoV-2 neutralizing antibodies derived from individuals infected with COVID-19.

From Absolute Antibody Ltd 18 Aug 2020

Study shows why young, female patients have low response rates to cancer immunotherapy

Cancer immunotherapy -- empowering a patient's own immune system to clear away tumors on its own -- holds great promise for some patients. But for other patients, immunotherapy just doesn't work.

18 Aug 2020

Majority of recovered COVID-19 patients have low neutralizing antibody titers

Now, a new study by researchers at New York University and published on the preprint server bioRxiv* in August 2020 reports on the type and intensity of anti-SARS-CoV-2 antibodies in recovered COVID-19 patients and the implications of these findings.

18 Aug 2020

Novel receptor protein may hold promise for treating COVID-19

A novel receptor protein that binds to the SARS-CoV-2 virus and prevents it from entering cells may hold promise for treating COVID-19 and other coronavirus-related diseases, according to research published online Aug. 4 in the journal SCIENCE.

17 Aug 2020

Mild COVID-19 cases can trigger robust memory T cell responses

Mild cases of coronavirus disease 2019 (COVID-19) can trigger robust memory T cell responses, even in the absence of detectable virus-specific antibody responses, researchers report August 14 in the journal Cell.

17 Aug 2020

Pre-COVID-19 coronavirus immunity does not protect against SARS-CoV-2

A recent study by researchers in France that's currently available on the medRxiv* preprint server claims that having previous immunity against common coronaviruses (alpha and beta) cannot protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Aug 2020

Wits University begins South African trial of Novavax COVID-19 vaccine

NVX-CoV2373 is produced by the biotech company, Novavax (Maryland, U.S.A). Novavax is a late-stage biotechnology company that develops next-generation vaccines for serious infectious diseases.

17 Aug 2020

FDA approves drug for treatment of neuromyelitis optica spectrum disorder

The U.S. Food and Drug Administration has approved Enspryng (satralizumab-mwge) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults with a particular antibody - patients who are anti-aquaporin-4 or AQP4 antibody-positive.

17 Aug 2020

Genome analysis helps detect 568 genes that drive cancer

Analysis of the genomes of 28,000 tumors from 66 types of cancer has led to the identification of 568 cancer driver genes

17 Aug 2020

Cyborg technology: Researchers take new step toward integrating electronics with the body

Although true "cyborgs" -; part human, part robotic beings -; are science fiction, researchers are taking steps toward integrating electronics with the body.

17 Aug 2020

Back-pain patients taking opioid painkillers produce anti-opioid antibodies

University of Wisconsin-Madison scientists have discovered that a majority of back-pain patients they tested who were taking opioid painkillers produced anti-opioid antibodies.

17 Aug 2020

With COVID vaccine trial, rural Oregon clinic steps onto world stage

From the outside, it appears to be just another suburban allergy clinic, a tidy, tan brick-and-cinder-block building set back from a busy highway and across the road from an auto parts store.

17 Aug 2020

Scientists claim signs of lasting SARS-CoV-2 immunity

Questions have been raised by many health experts on whether being infected with SARS-CoV-2 brings lasting immunity. Now, scientists have uncovered signs of strong and lasting immunity in people who even had a mild illness of COVID-19.

17 Aug 2020

Coronacept - A trap-and-destroy molecule against SARS-CoV-2

A new study published on the preprint server bioRxiv* in August 2020 reports a novel engineered molecule based on human and other mammalian orthologues of ACE2 fused with the Fc part of the antibody. This molecule interacts more tightly with the viral receptor-binding domain (RBD) to constitute a powerful immunoadhesin that targets the virus for destruction.

17 Aug 2020

Targeting SARS-CoV-2 with off-the-shelf CAR-NK cells

The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread and cause disease and death in many countries even today. At present, there is no effective treatment. A recent study published on the preprint server bioRxiv in August 2020 reports the potential of a new class of drugs called CAR NK cells, which could be used off-the-shelf to treat this disease.

17 Aug 2020

SARS-CoV-2 spike pocket is a putative target for antiviral design

In a methodologically rigorous study, researchers from the University of Oxford have recently shown how the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein harbors a lipid-binding pocket which modulates the stability of the prefusion trimer and provides conformational shielding from antibodies. Their findings are currently freely available on the bioRxiv* preprint server.

16 Aug 2020

Frequently used serology test may not detect SARS-CoV-2 antibodies, shows study

Two different types of detectable antibody responses in SARS-CoV-2 (COVID-19) tell very different stories and may indicate ways to enhance public health efforts against the disease, according to researchers at The University of Texas MD Anderson Cancer Center.

15 Aug 2020